Johnson & Johnson: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 13 October 2026: press release. Guidance figures: 5 raised, 1 kept. The quarter’s numbers.

Key takeaways

Reported sales rose 5.9%: Reported sales were $25.4 billion against $24.0 billion a year earlier, with operational growth of 6.0% and adjusted operational growth of 6.1%. Source
GAAP net earnings and EPS fell sharply: Net earnings were $210 million against $5,152 million, down 95.9%; diluted EPS was $0.09 against $2.12, down 95.8%. Source
Innovative Medicine grew 7.9%: Innovative Medicine sales were $16,757 million, up 7.7% reported and 7.9% operational, with divestitures reducing growth by 10 basis points. Source
Reported sales guidance raised: Estimated 2026 reported sales are $101.0 billion to $101.4 billion, midpoint $101.2 billion, up 7.4%; the July midpoint was $101.1 billion. Source
Adjusted EPS midpoint raised by $0.06: Adjusted EPS guidance is $11.05 to $11.15, midpoint $11.10, up 2.9%. The Q2 release gave a July range of $11.60 to $11.75, which this release's July column does not match. Source
Talc resolution charge in EPS: Third-quarter EPS includes a one-time special charge linked to the proposed resolution of ovarian talc litigation, announced in the quarter. Source
IMAAVY approved for wAIHA: The FDA approved IMAAVY for warm autoimmune hemolytic anemia, which the release describes as the first treatment for this condition. Source
OTTAVA authorized in the U.S.: FDA granted market authorization to the OTTAVA robotic surgical system, described as the first table-integrated soft tissue robotic system. Source

“In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma.”
Joaquin Duato, Chairman and Chief Executive Officer

Guidance

Area	Period	Figure	Against last quarter
Estimated reported sales Source	Full year 2026	$101.0B - $101.4B; midpoint $101.2B; 7.2% - 7.6%, midpoint 7.4%	Raised from $100.8B - $101.4B; midpoint $101.1B; 7.0% - 7.6%, midpoint 7.3% (July 2026)
Operational sales Source	Full year 2026	$100.5B - $100.9B; midpoint $100.7B; 6.7% - 7.1%, midpoint 6.9%	Raised from $100.3B - $100.9B; midpoint $100.6B; 6.5% - 7.1%, midpoint 6.8% (July 2026)
Adjusted operational sales growth Source	Full year 2026	6.4% - 6.8%, midpoint 6.6%	Raised from 6.2% - 6.8%, midpoint 6.5% (July 2026)
Adjusted EPS (diluted) Source	Full year 2026	$11.05 - $11.15; midpoint $11.10; 2.4% - 3.3%, midpoint 2.9%	Raised from $11.68 midpoint in the Q2 2026 release [P]; $11.04 midpoint in the July column of this release [A]
Adjusted operational EPS (diluted) Source	Full year 2026	$10.95 - $11.05; midpoint $11.00; 1.5% - 2.4%, midpoint 2.0%	Raised from $10.94 midpoint in the July column of this release [A]; $11.58 midpoint in the Q2 release [P]
Euro average rate assumption Source	Full year 2026 guidance	$1.15	Kept

What changed from last quarter

Guidance raised: Reported sales guidance lower end and midpoint raised; midpoint now $101.2 billion against $101.1 billion in July. Source
Guidance raised: Adjusted EPS guidance midpoint increased by $0.06 to $11.10, per the release. Source
Guidance raised: Adjusted operational sales growth midpoint raised from 6.5% to 6.6%. Source
Guidance kept: Illustrative euro average rate for guidance held at $1.15 in both July and October 2026. Source
New: Firefly Bio, Inc. acquisition reported as completed; the Q2 release had described it as an agreement to acquire. Source
New: Collaboration with Sail Biomedicines announced, covering in vivo CAR-T programs for autoimmune disease. Source
New: Proposed resolution of ovarian talc litigation announced in the quarter; the Q2 release did not include it. Source
New: Jennifer Taubert retiring as Executive Vice President; Tom Cavanaugh appointed EVP, Worldwide Chairman, Innovative Medicine, effective September. Source

Quarter results and growth

Reported sales rose 5.9%: Reported sales were $25.4 billion against $24.0 billion a year earlier, with operational growth of 6.0% and adjusted operational growth of 6.1%. Source
GAAP net earnings and EPS fell sharply: Net earnings were $210 million against $5,152 million, down 95.9%; diluted EPS was $0.09 against $2.12, down 95.8%. Source
Full-year guidance raised: The release headline states the company raised 2026 guidance, covering reported sales, operational sales and adjusted EPS. Source

Segments and regions

Innovative Medicine grew 7.9%: Innovative Medicine sales were $16,757 million, up 7.7% reported and 7.9% operational, with divestitures reducing growth by 10 basis points. Source
MedTech sales grew 2.5%: MedTech sales were $8,642 million, up 2.5% both reported and operational, against $8,430 million a year earlier. Source
U.S. grew faster than International: U.S. sales were $14,959 million, up 9.1%. International sales were $10,440 million, up 1.5% reported and 1.9% adjusted operational. Source

“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Joaquin Duato, Chairman and Chief Executive Officer

Franchise drivers and drags

TREMFYA and oncology lead growth: Innovative Medicine growth was led by TREMFYA, new Other Immunology products, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE and ERLEADA, plus SPRAVATO and CAPLYTA in Neuroscience. Source
OPSUMIT and IMBRUVICA declined: Growth was partly offset by declines in OPSUMIT/OPSYNVI and IMBRUVICA, with SIMPONI and REMICADE also named among the offsets. Source
MedTech drivers named: MedTech growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics. Source

Earnings adjustments and cash

Adjusted net earnings and EPS declined: Adjusted net earnings were $6,339 million against $6,801 million, down 6.8%; adjusted diluted EPS was $2.59 against $2.80, down 7.5%. Source
Non-GAAP measures exclude amortization: Adjusted measures exclude after-tax intangible amortization and special items; reconciliations appear in the accompanying financial schedules and on the company website. Source
Free cash flow estimated near $15.1 billion: Year-to-date free cash flow is estimated at about $15,100 million, against $14,226 million a year earlier, as of October 13, 2026. Source

2026 guidance

Reported sales guidance raised: Estimated 2026 reported sales are $101.0 billion to $101.4 billion, midpoint $101.2 billion, up 7.4%; the July midpoint was $101.1 billion. Source
Adjusted EPS midpoint raised by $0.06: Adjusted EPS guidance is $11.05 to $11.15, midpoint $11.10, up 2.9%. The Q2 release gave a July range of $11.60 to $11.75, which this release's July column does not match. Source
Adjusted operational EPS midpoint $11.00: Adjusted operational EPS guidance is $10.95 to $11.05, midpoint $11.00, up 2.0%. The July column here shows $10.94; the Q2 release showed $11.58. Source
Operational sales guidance raised: Operational sales guidance is $100.5 billion to $100.9 billion, midpoint $100.7 billion, up 6.9%, against a July midpoint of $100.6 billion. Source
Adjusted operational growth 6.4% to 6.8%: Adjusted operational sales growth guidance is 6.4% to 6.8%, midpoint 6.6%, against a July midpoint of 6.5%. Source
Euro rate assumption held at $1.15: The guidance uses an illustrative euro average rate of $1.15 for both July and October 2026. Source

Legal charge, deals and leadership

Talc resolution charge in EPS: Third-quarter EPS includes a one-time special charge linked to the proposed resolution of ovarian talc litigation, announced in the quarter. Source
Firefly Bio acquisition completed: The Firefly Bio, Inc. acquisition closed in the quarter, with the stated aim of advancing next-generation oncology innovation. Source
Sail Biomedicines collaboration announced: Johnson & Johnson announced a collaboration with Sail Biomedicines on in vivo CAR-T programs aimed at transforming autoimmune disease through immune reset. Source
Taubert retires; Cavanaugh named: Jennifer Taubert, Executive Vice President, is retiring; Tom Cavanaugh was appointed EVP, Worldwide Chairman, Innovative Medicine, effective September. Source

Approvals and clinical data

IMAAVY approved for wAIHA: The FDA approved IMAAVY for warm autoimmune hemolytic anemia, which the release describes as the first treatment for this condition. Source
OTTAVA authorized in the U.S.: FDA granted market authorization to the OTTAVA robotic surgical system, described as the first table-integrated soft tissue robotic system. Source
RYBREVANT FASPRO gets priority review: FDA granted priority review to RYBREVANT FASPRO for advanced head and neck cancer, described as a potential first-in-class EGFR- and MET-targeted subcutaneous treatment. Source
TECVAYLI and TALVEY reduced risk: In earlier-line relapsed or refractory multiple myeloma, TECVAYLI plus TALVEY reduced progression or death risk by 89% and death risk by 62%. Source
CARVYKTI five-year remission data: Five-year treatment-free remission was reported in 50% of patients after a single CARVYKTI infusion in early-line relapsed or refractory multiple myeloma. Source
CAPLYTA bipolar mania Phase 3 result: CAPLYTA showed significant and rapid improvement in bipolar mania in a pivotal Phase 3 study, per the release. Source

Figures management reported

Figure	Reported
STELARA impact on Innovative Medicine growth Source	approximate 690 basis points
FDA approval, IMAAVY for wAIHA Source	approved
FDA market authorization, OTTAVA Source	authorized
FDA priority review, RYBREVANT FASPRO Source	priority review, advanced head and neck cancer
TECVAYLI plus TALVEY trial results Source	89% lower risk of progression or death; 62% lower risk of death
CARVYKTI five-year treatment-free remission Source	50% of patients
CAPLYTA Phase 3, bipolar mania Source	significant and rapid improvement
ICOTYDE long-term data Source	2-year results in plaque psoriasis

Risks management discussed

Demand: The release names STELARA first among the offsets to Innovative Medicine growth, at an approximate 690 basis points impact. Source
External: Currency reduced International growth: International sales rose 1.5% reported against 1.8% operational growth, and worldwide currency lowered growth by 0.1 points. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals
Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint
Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer

New Brunswick, N.J. (October 13, 2026) - Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.

“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”

Overall financial results

	Q3
($ in Millions, except EPS)	2026	2025	% Change
Reported Sales	$25,399	$23,993	5.9%
Net Earnings	$210	$5,152	(95.9)%
EPS (diluted)	$0.09	$2.12	(95.8)%
	Q3
Non-GAAP* ($ in Millions, except EPS)	2026	2025	% Change
Operational Sales			6.0%
Adjusted Operational Sales			6.1%
Adjusted Net Earnings	$6,339	$6,801	(6.8)%
Adjusted EPS (diluted)	$2.59	$2.80	(7.5)%
Free Cash Flow	~$15,100	$14,226

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Excludes the net impact of acquisitions and divestitures and translational currency

Excludes intangible amortization expense and special items

Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

Third-quarter YTD 2026 is estimated as of October 13, 2026

Regional sales results

Q3						% Change
($ in Millions)		2026		2025	Reported	Operational	Currency	AdjustedOperational
U.S.		$14,959		$13,708	9.1%	9.1	-	9.1
International	10,440		10,285		1.5	1.8	(0.3)	1.9
Worldwide		$25,399		$23,993	5.9%	6.0	(0.1)	6.1

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Excludes the net impact of acquisitions and divestitures and translational currency

Segment sales results

Q3						% Change
($ in Millions)		2026		2025	Reported	Operational	Currency	AdjustedOperational
Innovative Medicine		$16,757		$15,563	7.7%	7.9	(0.2)	8.0
MedTech	8,642		8,430		2.5	2.5	0.0	2.5
Worldwide		$25,399		$23,993	5.9%	6.0	(0.1)	6.1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Excludes the net impact of acquisitions and divestitures and translational currency

Third-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)	October 2026	July 29, 2026
Adjusted Operational SalesChange vs. Prior Year / Mid-point	6.4% - 6.8% / 6.6%	6.2% - 6.8% / 6.5%
Operational Sales/ Mid-pointChange vs. Prior Year / Mid-point	$100.5B - $100.9B /$100.7B 6.7% - 7.1% / 6.9%	$100.3B - $100.9B / $100.6B 6.5% - 7.1% / 6.8%
Estimated Reported Sales/ Mid-pointChange vs. Prior Year / Mid-point	$101.0B - $101.4B / $101.2B7.2% - 7.6% / 7.4%	$100.8B - $101.4B / $101.1B 7.0% - 7.6% / 7.3%
Adjusted Operational EPS (Diluted)/ Mid-pointChange vs. Prior Year / Mid-point	$10.95 - $11.05 / $11.001.5% - 2.4% / 2.0%	$10.86 - $11.01 / $10.94 0.7% - 2.1% / 1.4%
Adjusted EPS (Diluted) / Mid-pointChange vs. Prior Year / Mid-point	$11.05 - $11.15 / $11.102.4% - 3.3% / 2.9%	$10.96 - $11.11 / $11.04 1.6% - 3.0% / 2.3%

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

Non-GAAP financial measure; excludes the impact of translational currency

Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only)

Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.

Regulatory

Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

Data Releases

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis

Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma

CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Other

New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

Forward-looking statements notice

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Contacts
media-relations@its.jnj.com
investor-relations@its.jnj.com